Improving Outcomes for Patients with Psoriatic Arthritis: Integrating a Comprehensive, Patient-Centered Care Model into Your PracticePremiere Date: Monday, May 4, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, May 4, 2022
Note: Credit Is No Longer Available
|Alexis Ogdie-Beatty, MD, MSCE
Associate Professor of Medicine and Epidemiology
Perelman School of Medicine, University of Pennsylvania
Director, Penn Psoriatic Arthritis Clinic
Hospital of the University of Pennsylvania
Psoriatic arthritis (PsA), a serious and potentially disabling condition, affects approximately 30% of patients with psoriasis, with the joint involvement often occurring about 10 years after the appearance of skin disease. PsA causes not only physical and functional impairments but also has a negative impact on overall quality of life. While dermatologists have an important role in early detection of PsA, patients often have overlapping treatment needs that require collaborative care between dermatologists and rheumatologists.
Recent U.S. Food and Drug Administration (FDA) approvals of several agents for moderate-to-severe PsA have expanded the treatment armamentarium, and the management paradigm continues to evolve. However, PsA continues to be under-recognized, misdiagnosed, and inadequately treated.
In this CMEOCast podcast, expert faculty focus on the latest evidence on screening patients for PsA, individualizing treatment that considers patient-reported outcomes (PROs), and using patient-centered approaches for care, with the goal of optimizing patient outcomes.
At the end of this CE activity, participants should be able to:
- Employ screening and assessment strategies to diagnose patients with PsA in clinical practice.
- Integrate clinical evidence for targeted therapies when individualizing treatment for patients with PsA, including their effects on PROs.
- Implement comprehensive, multidisciplinary, patient-centered approaches to treating PsA, taking into account patient preference and presence of comorbidities.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize screening and assessment strategies to diagnose patients with PsA in clinical practice.
- Describe clinical evidence for targeted therapies when individualizing treatment for patients with PsA, including their effects on PROs.
- Explain comprehensive, multidisciplinary, patient-centered approaches to treating PsA, taking into account patient preference and presence of comorbidities.
Supported by educational grants from Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Dermatologists, rheumatologists, nurse practitioners, PAs, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.75 contact hours (0.075 CEUs) Universal Activity Number:
MOC Points available for Rheumatology and Internal Medicine Board Certified Physicians.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
By providing your ABIM number, you consent to have CME Outfitters and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of .75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Ogdie-Beatty reports that she receives grants from Amgen Inc.; Novartis; and Pfizer Inc. She is a consultant for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; Corrona; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novartis; and Pfizer Inc. Her husband has received other financial or material support in the form of royalties from Novartis.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Poshala Tish Aluwihare, PhD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).